Commerce Bank Buys 257 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Commerce Bank raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,217 shares of the biopharmaceutical company’s stock after acquiring an additional 257 shares during the period. Commerce Bank’s holdings in Regeneron Pharmaceuticals were worth $5,460,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of REGN. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at $26,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. MCF Advisors LLC grew its position in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the period. Criterion Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $37,000. Finally, Sutton Wealth Advisors Inc. grew its position in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 358 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $967.50, for a total transaction of $346,365.00. Following the sale, the executive vice president now owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Marion Mccourt sold 358 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $967.50, for a total value of $346,365.00. Following the sale, the executive vice president now directly owns 13,431 shares in the company, valued at approximately $12,994,492.50. The disclosure for this sale can be found here. Insiders have sold a total of 54,925 shares of company stock valued at $53,649,186 over the last 90 days. 8.83% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Bank of America increased their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $989.36.

Regeneron Pharmaceuticals Trading Up 0.5 %

NASDAQ:REGN opened at $985.02 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The business’s 50-day moving average price is $944.81 and its two-hundred day moving average price is $914.87. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $108.54 billion, a price-to-earnings ratio of 29.10, a PEG ratio of 2.03 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.34 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.